Drug Profile
Oxybutynin hydrochloride - Hisamitsu Pharmaceutical
Alternative Names: HOB-294; HP-5070; Neoxy Tape; OABLOK PATCHLatest Information Update: 28 Nov 2022
Price :
$50
*
At a glance
- Originator Hisamitsu Pharmaceutical
- Class Alkynes; Antispasmodics; Carbocyclic acids; Cyclohexanes; Diethylamines; Esters; Mandelic acids; Skin disorder therapies; Small molecules
- Mechanism of Action Cholinergic receptor antagonists; Muscarinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Overactive bladder
- Preregistration Hyperhidrosis
Most Recent Events
- 28 Nov 2022 Hisamitsu Pharmaceutical announces intention to receive approval for Hyperhidrosis in Japan 2023 (Hisamitsu Pharmaceutical pipeline, November 2022)
- 12 Oct 2022 Preregistration for Hyperhidrosis in Japan (Transdermal), prior to October 2022 (Hisamitsu Pharmaceutical pipeline, November 2022)
- 07 Oct 2020 Hisamitsu Pharmaceutical announces to submit regulatory application for Hyperhidrosis in 2022